Pages that link to "Q44915186"
Jump to navigation
Jump to search
The following pages link to Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol (Q44915186):
Displaying 50 items.
- Antipsychotic medication for early episode schizophrenia (Q24236683) (← links)
- Clozapine versus typical neuroleptic medication for schizophrenia (Q24240931) (← links)
- Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. (Q24609188) (← links)
- The cytokine model of schizophrenia: emerging therapeutic strategies (Q26865996) (← links)
- Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis (Q28540093) (← links)
- Neurophyisological and neurocognitive endophenotypes for schizophrenia genetics research (Q30484477) (← links)
- In vitro and in vivo demonstration of risperidone implants in mice. (Q30493152) (← links)
- Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (Q30536299) (← links)
- Neuropsychologic functioning and structural MRI of the brain in patients with schizophrenia (Q30988161) (← links)
- Structural MRI and brain development (Q31019051) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (Q33235110) (← links)
- Cognition, schizophrenia and the effect of antipsychotics (Q33250162) (← links)
- Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders (Q33563165) (← links)
- The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. (Q33605308) (← links)
- The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome (Q33707648) (← links)
- Modern antipsychotic drugs: a critical overview (Q33853390) (← links)
- Effect of second-generation antipsychotics on cognition: current issues and future challenges (Q33888153) (← links)
- Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients (Q33936458) (← links)
- Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia (Q33976994) (← links)
- The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys (Q33985626) (← links)
- Schizophrenia and the alpha7 nicotinic acetylcholine receptor (Q34002872) (← links)
- Retracted: Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia (Q34249753) (← links)
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents (Q34274859) (← links)
- Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. (Q34379248) (← links)
- Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis (Q34393431) (← links)
- The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. (Q34418847) (← links)
- Medication-free research in early episode schizophrenia: evidence of long-term harm? (Q34463497) (← links)
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia (Q34579324) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (Q34640811) (← links)
- Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials (Q34703195) (← links)
- Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview (Q34706665) (← links)
- Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis (Q34830869) (← links)
- Time-lapse mapping of cortical changes in schizophrenia with different treatments (Q35015837) (← links)
- Analyzing the influence of BDNF heterozygosity on spatial memory response to 17β-estradiol (Q35034804) (← links)
- Early intervention in psychotic disorders: Challenges and relevance in the Indian context (Q35135578) (← links)
- The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis. (Q35236574) (← links)
- Delay discounting and task performance consistency in patients with schizophrenia (Q35299154) (← links)
- The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? (Q35390239) (← links)
- Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial (Q35679935) (← links)
- Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). (Q35912043) (← links)
- New targets in the treatment of anorexia nervosa (Q36066305) (← links)
- Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders (Q36148536) (← links)
- The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement (Q36224865) (← links)
- First- and second-generation antipsychotic medication and cognitive processing in schizophrenia (Q36228233) (← links)
- The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review (Q36262544) (← links)
- Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia (Q36302850) (← links)
- EARLY DETECTION AND INTERVENTION FOR PSYCHOSIS: PERSPECTIVES FROM NORTH AMERICA. (Q36318838) (← links)
- Real-world cognitive--and metacognitive--dysfunction in schizophrenia: a new approach for measuring (and remediating) more "right stuff". (Q36362261) (← links)
- Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. (Q36414518) (← links)